

Thalidomide-O-amido-PEG2-C2-NH2 Biochemical

Thalidomide-O-amido-PEG2-C2-NH2

CATALOG #
AAA228008


PRODUCT SYNONYMS

Thalidomide-O-amido-PEG2-C2-NH2; VH032-C7-amine; Thalidomide-O-amido-PEG2-C2-NH2 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	1957235-74-3
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
S,R,S)-AHPC-C7-amine, CAS 2306389-04-6



Structure
S,R,S)-AHPC-C7-amine, CAS 2306389-04-6

ADDITIONAL INFORMATION

Related Product Information for Thalidomide-O-amido-PEG2-C2-NH2 biochemical	Thalidomide-O-amido-PEG2-C2-NH2 incorporates an E3 ligase ligand and a linker, can be an immunomodulator for the treatment of cancer.
References	1. Lijie Peng, et al. Identification of New Small-Molecule Inducers of Estrogen-related Receptor alpha (ERRalpha) Degradation. ACS Med Chem Lett. 2019 Apr 12;10(5):767-772.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.